Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjuvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE)

Chang Woo Kim, Byung Mo Kang, Ik Yong Kim, Ji Yeon Kim, Sun Jin Park, Won Cheol Park, Ki Beom Bae, Byung-Noe Bae, Seong Kyu Baek, Seung Hyuk Baik, Gyung Mo Son, Yoon Suk Lee and Suk-Hwan Lee

Abstract

Background: Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) has been a standard treatment option for locally advanced rectal cancer with improved local control. However, systemic recurrence despite neoadjuvant CRT remained unchanged. The only significant prognostic factor proven to be important was pathologic complete response (pCR) after neoadjuvant CRT. Several efforts have been tried to improve survival of patients who treated with neoadjuvant CRT and to achieve more pCR including adding cytotoxic chemotherapeutic agents, chronologic modification of chemotherapy schedule or adding chemotherapy during the perioperative period. Consolidation chemotherapy is adding several cycles of chemotherapy between neoadjuvant CRT and TME. It could increase pCR rate, subsequently could show better oncologic outcomes.

Methods: Patients with advanced mid or low rectal cancer who received neoadjuvant CRT will be included after screening. They will be randomized and assigned to undergo TME followed by 8 cycles of adjuvant chemotherapy (control arm) or receive 3 cycles of consolidation chemotherapy before TME, and receive 5 cycles of adjuvant chemotherapy (experimental arm). The primary endpoints are pCR and 3-year disease-free survival (DFS), and the secondary endpoints are radiotherapy-related complications, R0 resection rate, tumor response rate, surgery-related morbidity, and peripheral neuropathy at 3 year after the surgery. The authors hypothesize that the experimental arm would show a 15% improvement in pCR (15 to 30%) and in 3-year DFS (65 to 80%), compared with the control arm. The accrual period is 2 years and the follow-up period is 3 years. Based on the superiority design, one-sided log-rank test with α-error of 0.025 and a power of 80% was conducted. Allowing for a drop-out rate of 10%, 358 patients (179 per arm) will need to be recruited. Patients will be followed up at every 3 months for 2 years and then every 6 months for 3 years after the last patient has been randomized.

(Continued on next page)
Discussion: KONCLUDE trial aims to investigate whether consolidation chemotherapy shows better pCR and 3-year DFS than adjuvant chemotherapy alone for the patients who received neoadjuvant CRT for locally advanced rectal cancer. This trial is expected to provide evidence to support clear treatment guidelines for patients with locally advanced rectal cancer.

Trial registration: Clinicaltrials.gov NCT02843191 (First posted on July 25, 2016).

Keywords: Rectal cancer, Chemoradiotherapy, Consolidation chemotherapy, Pathologic complete response, Disease free survival

Background
Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is the standard treatment for local advanced mid- or low rectal cancer [1, 2]. Reduction of local recurrence has been proven after introduction of TME for rectal cancer [3]. Additionally, chemotherapy and/or radiotherapy have shown the roles to improve oncologic outcomes by controlling local recurrence. Preoperative chemoradiotherapy showed better outcomes compared with postoperative chemoradiotherapy or preoperative radiotherapy alone [4–8].

However, failure of systemic controls including liver, lung, peritoneum, or bone still remained even after CRT followed by TME [1, 4, 5]. Many efforts have been made to control micrometastatic disease and to prevent distant and local recurrence. So far, no reliable molecular or pathologic biomarkers to foster pathologic complete response (pCR), which means complete regression of the tumor after radiotherapy and/or chemotherapy, was identified. Meanwhile, patients who showed pCR have been reported with lower recurrence and better survival [9, 10]. Therefore, many trials have been performed to increase pCR rates by changing perioperative treatment strategies.

Prolongation of the interval between CRT and TME has shown to increase pCR rates [11]. The interval has prolonged recently from 6 to 8 weeks up to 12 weeks, and several authors reported that extending the interval showed better pCR rates without increasing morbidity. [12–15] Another tries to achieve more pCR were adding platinum analogue (i.e. oxaliplatin) or vascular endothelial growth factor antagonist (i.e. bevacizumab) preoperatively and/or postoperatively based on 5-FU [16–18]. Unfortunately most of them failed to show higher pCR rates but increased acute toxicity [19, 20]. Recent trials reported that changing sequence of chemotherapy cycles as well as chemotherapeutic agents would attain better pCR rates, and new trials are launching. The examples are induction chemotherapy, consolidation chemotherapy, and sandwich regimen (prior to, concurrently with, and following radiation therapy) [21–26]. Sandwich regimen with capecitabine and oxaliplatin accompanied by 25 Gy of radiotherapy resulted in 42.2% of pCR rates, and even 10% of patients needed no surgery because the patients had achieved clinical complete response [22].

Garcia-Aguilar et al. reported that pCR rates were significantly increased in the patients who received various cycles of consolidation chemotherapy of FOLFOX regimen without significantly increased toxicity [21]. Then they showed that additional consolidation chemotherapy resulted in higher pCR rates in their multicenter, phase 2 trial [23]. However, it is not sufficient to conclude that consolidation chemotherapy is the only affecting factor to pCR due to several limitations. The interval and duration of consolidation chemotherapy were variable from 6 to 20 weeks. Moreover, adjuvant chemotherapy after TME followed by CRT was not standardized, and the total doses or cycles of chemotherapy was not consistent equally. Therefore, well-designed randomized controlled trials to assess the effect of consolidation chemotherapy alone after neoadjuvant chemoradiotherapy for locally advanced mid or low rectal cancer is required.

Methods/design
Study design
This trial is a phase 3 trial investigating the efficacy of 3 cycles of consolidation chemotherapy between neoadjuvant CRT and TME for locally advanced rectal cancer. To prove the effects of consolidation chemotherapy, we will administer the equal schedules of chemotherapy (8 cycles of mFOLFOX6 chemotherapy) in both groups.

Patient selection criteria are as follows:

- Inclusion Criteria

1) An adult aged 20-75 years old
2) Histologically confirmed adenocarcinoma of mid or low rectum (i.e. the lower margin of tumor located below the peritoneal reflection or within 12 cm from the anal verge by digital rectal examination, rigid proctosigmoidoscopy or MRI measurement from sagittal T2 weighted image)
3) Locally advanced rectal cancer confirmed by magnetic resonance image (MRI): Clinical stage T1-3N1or2 or clinical stage cT3N0 (or depth of perirectal invasion by tumor > 5 mm on MRI), or
suspicious of circumferential invasion on MRI (or circumferential margin < 1 mm)
4) ECOG performance status of 0-2
5) ASA score of ≤ 3
6) An informed consent form has been signed by the patient.

– Exclusion Criteria

1) Upper rectal cancer (i.e. the lower margin of tumor located above the peritoneal reflection)
2) Clinical stage T1 or N0 on MRI
3) Clinical stage T4 Nany on MRI (T4 lesion would be complicated to manage)
4) Distant metastasis diagnosed by imaging diagnosis or histology
5) The patient received chemotherapy or radiotherapy during the past 6 months
6) The patient received any therapy for colorectal cancer or another malignancy during the past 5 years
7) The patient has severe underlying diseases or poor condition to receive chemotherapy or radiotherapy
8) Pregnant of breastfeeding women
9) The patient who participate in another clinical trial, or receives any drug for the trial
10) Uncontrolled peripheral neuropathy (> Grade 2)
11) Any unhealed wound, fracture, peptic ulcer, or intraabdominal abscess
12) Active gastrointestinal bleeding
13) Patients with an active infection, which needs antibiotic therapy, during the randomization period

All the patients who received CRT (50.4 Gy radiation with capecitabine 825 mg/m² twice daily for 28 days) will be randomized in a 1:1 ratio into one of the following arms after screening: conventional chemotherapy group (control arm: Arm 1) or consolidation chemotherapy group (experimental arm: Arm 2) (Fig. 1). Stratification factors are age (< 70 or ≥ 70), clinical T stage (T1/2 or T3), and clinical N stage (N0 or N1/2). All eligible patients will be enrolled from approval of institutional review board (IRB) at each participating institution. The accrual period is 2 years and the follow up period is 3 years. The screening program includes history taking, physical examinations, laboratory tests, chest X-ray, EKG, and so on. If abnormal results requiring treatment were found within the screening, the patient will be given a proper treatment and the enrollment can be cancelled.

Arm 1 (conventional chemotherapy group): the patients, who are allocated to the arm 1, will undergo TME at
Objective

The authors will compare pCR rates and 3-year disease-free survival (DFS) rates as the primary endpoints between the two groups. pCR is defined as no residual tumor or complete replacement of fibrosis in the surgical specimen (i.e. Mandard 1 or Dworak 4). 3-yr DFS is defined as proportion of the patients who survive without any local or distant recurrence/metastasis at the 3 years of follow up.

Secondary endpoints are radiotherapy-related toxicity, R0 resection rate, tumor response rate, surgery-related morbidity, and severity of peripheral neuropathy at 3 years. Acute and chronic toxicity will be recorded in the electronic case report form (eCRF). R0 resection rate is defined as the proportion of R0 resection among all TME specimens according to the pathologic results. TME quality evaluation will be performed by surgeons or pathologists: complete, nearly complete, and incomplete [30]. Tumor response rate is represented as grade of Mandard or Dworak [31, 32]. Postoperative complications within 30 days after TME will be recorded according to the grade of Clavien-Dindo classification of surgical complications [33]. Severity of peripheral neuropathy will be assessed at 3 years as well as every cycles of chemotherapy. The grade of any adverse event will be recorded by Common Terminology Criteria for Adverse Events (CTCAE) 4.0 [34]. Operative, pathologic, and chemotherapeutic reports are documented in the eCRF.

Sample size calculation and randomization

Based on literatures, pCR rates and 3-year DFS after CRT for rectal cancer were known to be 10 to 28% and 50-65%, respectively [2, 6, 8–13]. Thus we hypothesize that the experimental arm would show a 15% improvement in pCR and in 3-year DFS, compared with the control arm (15 to 30% and 65 to 80%, respectively). The accrual period is 2 years and the follow-up period is 3 years. Based on the superiority design, one-sided proportion test and log-rank test with α-error of 0.025 and a power of 90% was conducted for both primary endpoints: pCR and 3-year DFS. The pCR of each group was considered to be 15 and 30%, and the 3-year DFS of each group was considered to be 65 and 80% assuming that accrual time was 2 years and follow up time was 3 years. Allowing neoadjuvant CRT for a dropout rate of 10%, 358 patients (179 per arm) for pCR and 316 patients (158 per arm) for 3-year DFS will need to be recruited. Therefore a total of 358 participants (among 358 and 316) are needed. This study of 358 participants had at least 81% power (90% each = 0.9, so 0.9 × 0.9 = 0.81) to simultaneously detect a difference of pCR and 3-year DFS of two groups. Randomization will be performed in a 1:1 ratio by computer-generated random numbers, with the use of stratified permuted 4 blocks. It will stratified according to age (< 70 vs. ≥70), clinical T stage (T1/2 or T3), and clinical N stage (N0 or N1/2). Among 8 strata, 2 strata will not be used because clinical T1/2 N0 (age <70 and ≥70) are not indicated for neoadjuvant CRT.

Data collection and management

The authors employ a web-based clinical research management system (Healthroad, Seoul, Republic of Korea), which gathers clinical data and information through on-line (konclude.e-trial.co.kr, Fig. 2). Principal investigators or clinical research coordinators in each site should sign up and enter clinical data onto an eCRF. Approved researchers of central data managing institution will manage the data and information. Only the principal investigator...
can access the final trial dataset and analyze them. Personal information of enrolled patients will be maintained for 5 years in order to protect confidentiality.

**Drop-out**
A patient can be dropped out in cases as follows:

1) Not acceptable adverse events related to surgery or chemotherapy
2) Different treatment needs which not approved in this trial
3) A patient’s refusal by any reasons
4) A patient’s pregnancy

**Statistical analysis**
Continuous variables will be analyzed with independent two sample t-test, whereas categorical variables will be analyzed with Chi-square test or Fisher’s exact test. 3-yr DFS will be analyzed with Kaplan-Meier curve. The difference between both Arms will be compared by Cox’s proportional hazards model. Interim analysis for pCR will be performed after TME of the last enrolled patient with Cochran-Mantel-Haenszel test. P-value less than 0.05 will be considered as significant. All analyses will be performed with SPSS version 20.0.

**Table 1** pCR by adding Oxaliplatin to 5-FU for rectal cancer

| Trial          | N  | Regimen                      | pCR rate       |
|----------------|----|------------------------------|----------------|
| STAR-01        | 705| 5-FU vs. 5-FU + Oxaliplatin  | 16% vs. 16% (p = 0.904) |
| ACCORD 12      | 598| Capecitabine vs. CAPOX       | 13.9% vs. 19.2% (p = 0.09) |
| NSABP R-04     | 1608| 5-FU vs. 5-FU + Oxaliplatin vs. Capecitabine vs. CAPOX | 17.8% vs. 19.5% (p = 0.42) |
| CAO/ARO/AIO-04 | 1236| 5-FU vs. 5-FU + Oxaliplatin  | 13% vs. 17% (p = 0.031) |
| PETACC-6       | 1094| Capecitabine vs. CAPOX       | 11.3% vs. 13.3% (p = 0.31) |
| Dallas et al.  | 70 | CAPOX + Bevacizumab          | 17.4%          |
| EXPERT-C       | 165| CAPOX vs CAPOX + Cetuximab   | 7% vs. 11% (p = 0.714) |

*pCR* pathologic complete response, 5-FU 5-fluorouracil, CAPOX capecitabine with oxaliplatin

**Safety evaluation and reporting of adverse effect**
Adverse events and serious adverse events must be reported to protect patients. Radiotherapy-related toxicity, chemotherapy-related toxicity, and surgery-related morbidity will be recorded onto the eCRF. Serious adverse events will be reported every quarter of the year, whereas suspected, unexpected, serious, adverse reaction, which could result in death or life threatening, will be reported within 15 days from the detection by investigators.

**Data monitoring**
A committee will be organized for trial supervision. All members of the committee are certified according to the course of good clinical practice in each institution. All process including data collection, record, and management will be monitored by them. The committee can advise and request the principal investigator to change some plans.

**Protocol modification**
If needed, the protocol can be modified by communication and agreement of the principal investigator and trial participants with revising its version.
Discussion
Despite fundamental role of 5-FU as neoadjuvant and adjuvant regimen for advanced colorectal cancer, addition of various cytotoxic agents has been tried to improve oncologic outcomes. Among them was oxaliplatin, a platinum analogue (Table 1). FOLFOX as adjuvant regimen for locally advanced rectal cancer showed superior DFS compared with 5-FU or capecitabine alone in ADORE trial and the German CAO/ARO/AIO-04 study [35, 36], although it failed to show better oncologic outcomes but more proportion of acute toxicity as neoadjuvant regimen [7, 17, 18]. Surgical and medical oncologists concluded that FOLFOX is only efficient as adjuvant setting, not neoadjuvant for rectal cancer. Then, can FOLFOX show higher pCR rates without increasing acute toxicity in the position between neoadjuvant and adjuvant? This is the point that KONCLUDE trial concentrates on.

As aforementioned, several authors already reported high pCR rates from consolidation chemotherapy without significantly increasing toxicity, while a couple of trials are on-going [21–25]. However, there were a few, but meaningful limitations in their studies including characters of phase 2 trial, variation of the resting period between radiotherapy and TME, and difference of total cycles of chemotherapy. These studies cannot establish the treatment guideline because of their inherited bias. Therefore, we adjusted total cycles of chemotherapy as 8 cycles of mFOLFOX6 to avoid inherited bias due to different cycles of chemotherapy. Moreover, we fixed the interval between radiotherapy and TME as 9 weeks, according to previous literatures which commented appropriate resting period as 6 to 12 weeks, to investigate efficacy of consolidation without confounding of various duration of interval from completion of CRT to TME.

KONCLUDE trial started with the first enrollment in December 7, 2016 after the registration on clinicaltrials.gov in July 25, 2016 (NCT02843191). We expect that this trial will conclude whether consolidation chemotherapy would attain higher pCR and improved DFS or not, providing a critical clue to establish the standard treatment in locally advanced mid- or low rectal cancer with level 1 evidence.

Funding
The study is an investigator-initiated trial with a limited fund by Korean Society of Coloproctology (KSCP). However, KSCP has no role in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, etc.

Authors’ contributions
CWK and SHL have made substantial contributions to the conception and design of the study, have been involved in drafting the manuscript or revising it critically for important intellectual content and gave final approval of the version to be published. BMK, HYK, JYK, SJP, WCP, KBB, BNB, SKB, SHB, GMS, and YSL have made contributions to the design of the study and gave substantial contributions to the organization of this trial. All authors have given final approval of the version to be published; and are local investigators at the participating centers.

Ethics approval and consent to participate
The authors follow either the Declaration of Helsinki to protect the patients, and the trial will be performed according to the ICH-GCP guidelines. The institutional review board of the principal investigator (S-H Lee) approved the trial (KHWMC 2016-04-042-001) at Kyung Hee University Hospital at Gangdong. Moreover, the full lists of ethics committees that approved the trial are as follows: IRB 2016-106 at Chunchun Sacred Heart Hospital, CR316102 at Wonju Severance Christian Hospital, IRB 2016-11-015 at Chungnam National University Hospital, IRB 2017-02-053 at Kyung Hee Medical Center, WKUH 2017-02-008-001 at Wonkwang University Hospital, IRB 16-0242 at Inje University Busan Paik Hospital, SGAPIK 2016-09-001-004 at Inje University Sanggye Paik Hospital, DSMC 2016-09-022-001 at Keimyung University Dongsan Medical Center, IRB 3-2017-0019 at Gangnam Severance Hospital, IRB 05-2016-179 at Pusan National University Yangsan Hospital, IRB 2017-4239-0001 at Seoul St. Mary’s Hospital. All patients will understand and agree to the aims and process of the trial, possible results and risks. An informed consent has to be written in the language which patients can understand, and be explained by an investigator. If patients cannot read an informed consent, an investigator has to read it in the presence of a witness. Although a patient signed an informed consent at first, an investigator has to stop a process of the patient when he or she refuses. A copy of signed informed consent should be provided to the patient. An original copy will be an investigator’s safekeeping.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, South Korea. Department of Medicine, the Graduate School of Yonsei University, 50-1 Yonsei-ro, Seoul, South Korea. 2Department of Surgery, Chunchun Sacred Heart Hospital, Hallym University College of Medicine, 77 Salju-ro, Chunchun, South Korea. 3Department of Surgery, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju, South Korea. 4Department of Surgery, Chungnam National University Hospital, Chungnam National University College of Medicine, 282 Munhwa-ro, Daejeon, South Korea. 5Department of Surgery, Kyung Hee Medical Center, Kyung Hee University School of Medicine, 23 Kyung Hee dae-ro, Seoul, South Korea. 6Department of Surgery, Wonkwang University Hospital, Wonkwang University School of Medicine, 895 Muwang-ro, Iksan, South Korea. 7Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, 75 Boji-ro, Busan, South Korea. 8Department of Surgery, Inje University Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-ro, Seoul, South Korea. 9Department of Surgery, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, 56 Daedong-ro, Daegu, South Korea. 10Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ru, Seoul, South Korea. 11Department of Surgery, Pusan National University Yangsan Hospital, Pusan University College of Medicine, 20 Geumo-ro, Yangsan-si, South Korea.

Abbreviations
S-FU: 5-fluorouracil; CRT: chemoradiotherapy; DFS: disease-free survival; eCRF: electronic case report form; FOLFOX: 5-FU and leucovorin with oxaliplatin; KONCLUDE: Korean society of coloproctology trial of cONSolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjuvant concurrent chemoroDithErapy: a multicenter, randomized controlled trial; pCR: pathologic complete response; TME: total mesorectal excision

Acknowledgements
The authors wish to thank Drs. Kwang Ho Kim, Moo-Jun Baek, Eung Jin Shin, Jun Won Um, and Seong Taek Oh for their participation in the KONCLUDE trial.
1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.

2. Guillem JG, Chessin DB, Cohen AM, Shia J, Muzumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Salsz L, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):825–36. Discussion 836-828.

3. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer—tissue to pelvic cure? Br J Surg. 1982;69(10):613–6.

4. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, van Groeningen CJ, van Lanschot JJ, van Leyden Y, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FRTC 9203. J Clin Oncol. 2006;24(28):4620–5.

5. Sauer R, Liensch T, Meikle S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.

6. Roh MS, Calonge LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):4924–30.

7. Rodel C, Martus P, Papadopoulos T, Fuzei L, Klimpfinger M, Fietkau R, Liensch T, Hohenberger W, Raab R, Sauer R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(9):1888–96.

8. Garcia-Aguilar J, Hernandez de Anda A, Srivongs P, Lee SH, Madoff RD, Rothenberger DA: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003, 46(3):298-304.

9. Francois Y, Meneau C, Baukeu J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeline P, Gerard JP. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R95-01 randomized trial. J Clin Oncol. 1999;17(8):2396.

10. Tučinský H, Shmueli E, Figer A, Kauenser JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661–7.

11. Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Petrelli NJ, et al. Neoadjuvant therapy for rectal cancer: the Lyon R95-01 randomized trial. J Clin Oncol. 2011;29(18):2773–80.

12. Gerard JP, Azia D, Goourgou-Bourgade S, Martel-Lafaye I, Hernequin C, Etienne PL, Vendrey V, Francois E, de La Roche G, Bouche O, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Progide 2. J Clin Oncol. 2010;28(10):1638–44.

13. Aschele C, Cioni L, Lonardi S, Pinto C, Cordio S, Rosati G, Antale S, Tagliagambe A, Ambrosini G, Rossetti P, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.

14. Gerard JP, Azia D, Goourgou-Bourgade S, Martel-Lafaye I, Hernequin C, Etienne PL, Vendrey V, Francois E, de La Roche G, Bouche O, et al. Clinical outcome of the ACCORD 12/0405 PROGIDE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–65.

15. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdemonta J, Chung DC, Fischman AJ, Lauwers GY, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27(18):3020–6.

16. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer—clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20(7):1729–34.

17. Weisberg MR, Klimstra DS, Saltz L, et al. Adjuvant therapy for colon cancer: results of NSABP R-03 trial, including survival and subset analyses. J Clin Oncol. 2009;27(18):2773–80.

18. Stein BN, Petrelli NJ, Douglas HG, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75(1):11–7.

19. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17(8):2412–8.

20. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Calonghe LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–74.

21. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Calonghe LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–74.

22. Kim et al. BMC Cancer (2018) 18:538

Page 7 of 8
35. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JH, Kim SY, Kim TY, Kim JH, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–53.

36. Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.